ImmunoCellular Therapeutics (FRA:KOL1) Dividends per Share : €0.00 (TTM As of Jun. 2018)

View and export this data going back to . Start your Free Trial

What is ImmunoCellular Therapeutics Dividends per Share?

ImmunoCellular Therapeutics's dividends per share for the three months ended in Jun. 2018 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00. Its Dividend Payout Ratio for the three months ended in Jun. 2018 was 0.00. As of today, ImmunoCellular Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

ImmunoCellular Therapeutics Dividends per Share Historical Data

The historical data trend for ImmunoCellular Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoCellular Therapeutics Dividends per Share Chart

ImmunoCellular Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dividends per Share

Get a 7-Day Free Trial

ImmunoCellular Therapeutics Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ImmunoCellular Therapeutics's Dividends per Share

For the Biotechnology subindustry, ImmunoCellular Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoCellular Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoCellular Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where ImmunoCellular Therapeutics's Dividend Yield % falls into.

ImmunoCellular Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

ImmunoCellular Therapeutics (FRA:KOL1) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ImmunoCellular Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2018 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2018 )	/	EPS without NRI (Q: Jun. 2018 )
	=	0	/	-0.009
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

ImmunoCellular Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of ImmunoCellular Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoCellular Therapeutics (FRA:KOL1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoCellular Therapeutics Ltd (FRA:KOL1) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645

Website

https://www.eompharma.com

EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

ImmunoCellular Therapeutics (FRA:KOL1) Headlines

No Headlines